Internal Pipeline
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Market | |
|---|---|---|---|---|---|
|
Marketed In development
|
|||||
| 1.Please visit www.KALBITOR.com for Important Safety Information and Full Prescribing Information including Boxed Warning and Medication Guide 2.Retinal Vein Occlusion (RVO). Partnered with Fovea Pharmaceuticals (sanofi-aventis) in EU *Investigator-sponsored trial for ecallantide in ACE inhibitor-induced angioedema |
|||||
| KALBITOR® (ecallantide)1 | |||||
| Hereditary Angioedema (HAE) |
|||||
| Ecallantide | |||||
| ACE inhibitor-induced angioedema* | |||||
| Retinal vein occlusion (RVO) induced macular edema2 | |||||
| 5+ programs in niche indications |
|||||